Celltrion, Inc.
068270
Classement en actions
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Prix de l'action
$146.63
Capitalisation boursière
$33.44B
Changement (1 jour)
-1.52%
Changement (1 an)
23.60%
Pays
KR
Échange Celltrion, Inc. (068270)
Catégorie
Healthcare
Revenus pour Celltrion, Inc. (068270)
Revenus en Jun 2026 TTM : $3.69B
Selon les derniers rapports financiers de Celltrion, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $3.69B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $2.42B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $1.68B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Celltrion, Inc. de 2007 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $3.69B | 28.08% |
| 2025 | $2.88B | 19.08% |
| 2024 | $2.42B | 43.92% |
| 2023 | $1.68B | -7.11% |
| 2022 | $1.81B | 13.65% |
| 2021 | $1.59B | -6.50% |
| 2020 | $1.70B | 74.29% |
| 2019 | $977.23M | 10.80% |
| 2018 | $881.97M | -0.96% |
| 2017 | $890.53M | 60.12% |
| 2016 | $556.15M | 8.32% |
| 2015 | $513.45M | 19.28% |
| 2014 | $430.46M | 100.34% |
| 2013 | $214.86M | -34.69% |
| 2012 | $328.97M | 36.64% |
| 2011 | $240.76M | 49.20% |
| 2010 | $161.36M | 28.65% |
| 2009 | $125.42M | 93.41% |
| 2008 | $64.85M | 1.02% |
| 2007 | $64.19M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 242.09% |
US
|
|
| $2.23B | -39.63% |
US
|
|
| $15.74B | 326.63% |
AU
|
|
| $9.57B | 159.39% |
BE
|
|
| $6.02B | 63.16% |
NL
|
